Trelegy Ellipta (Fluticasone, Umeclidinium, Vilanterol)

purchase Trelegy from canada

Trelegy Ellipta (Fluticasone, Umeclidinium, Vilanterol)

Vilanterol Trifenatate Umeclidinium Bromide Fluticasone Furoate


Product information

Trelegy Ellipta - available online from Canada! Trelegy is an inhaler used to treat chronic obstructive pulmonary disease (COPD) and asthma. It contains three medications—fluticasone, umeclidinium, and vilanterol—that work together to reduce inflammation, relax airway muscles, and improve breathing. Trelegy is taken once daily to help control symptoms like shortness of breath and coughing. It is not a rescue inhaler and should be used regularly for best results.

In stock and ready to ship.

Prescription Required • Product of Canada • Shipping from Canada

Product options

SAVE on TRELEGY ordering online from Canada! (USA Prescription Required)

 

TRELEGY ELLIPTA - Canada Product Information



A video recording of Trelegy Ellipta may be seen here


Trelegy Ellipta is a medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It combines three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. These components work together to help you breathe easier by reducing inflammation, relaxing airway muscles, and opening the airways in your lungs.


TRELEGY ELLIPTA IS PRESCRIBED FOR:
  • Adults with COPD: Especially those not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) or a long-acting muscarinic antagonist (LAMA) and a LABA.
  • Adults with Asthma: Who are not adequately controlled with a maintenance combination of a medium or high dose of an ICS and a LABA.
 
IMPORTANT SAFETY INFORMATION
  • Not for Acute Relief: Trelegy Ellipta is not for the relief of acute bronchospasm or sudden breathing problems. Use a fast-acting inhaler (e.g., salbutamol) for sudden symptoms.
  • Hypersensitivity: Do not use if you are allergic to fluticasone furoate, umeclidinium, vilanterol, or any ingredients in the formulation. This includes severe milk protein allergy.
  • Use with Caution: Inform your doctor if you have heart problems, high blood pressure, seizures, thyroid problems, diabetes, liver disease, or eye problems like glaucoma.
  • Side Effects: Common side effects include nasopharyngitis (cold-like symptoms), headache, back pain, and respiratory infections. Seek medical attention if you experience severe reactions like difficulty breathing, swelling of the face, or severe rash.
 
HOW TO USE TRELEGY ELLIPTA
  • Dosage: Use one inhalation once daily, at the same time each day.
  • Missed Dose: If you miss a dose, take it as soon as you remember. If it’s close to your next dose, skip the missed dose. Do not take two doses at once.
  • Inhalation Technique: Breathe out fully, place the mouthpiece between your lips, and inhale deeply. Hold your breath for about 10 seconds, then exhale slowly. Rinse your mouth with water after inhaling to reduce the risk of oral infections.
 
STORAGE AND HANDLING
  • Storage: Keep Trelegy Ellipta at room temperature, away from direct heat and sunlight. Keep it dry.
  • Disposal: Dispose of the inhaler 6 weeks after opening or when the dose counter reads "0," whichever comes first.

WHEN TO CONTACT YOUR DOCTOR
  • Worsening Symptoms: If you notice worsening breathing problems or increased frequency of asthma attacks.
  • Infections: If you develop symptoms of pneumonia such as fever, chills, increased cough, or changes in sputum color.
  • Side Effects: If you experience serious side effects such as chest pain, severe dizziness, or severe allergic reactions.
 
SUPPLIED

Trelegy from Canada consists of an inhaler device with a plastic light grey body, a beige mouthpiece cover and a dose counter. The inhaler device encompasses two double foil blister strips both having 30 blisters. On one strip, each blister contains a white dry powder mixture of micronized fluticasone furoate (100 or 200 mcg) and lactose monohydrate. On the other strip, each blister contains a white dry powder mixture of micronized umeclidinium bromide (74.2 mcg, equivalent to 62.5 mcg of umeclidinium), micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), lactose monohydrate and magnesium stearate. The lactose monohydrate contains milk proteins. After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream created by the patient inhaling through the mouthpiece.


Always follow your doctor's instructions and read the leaflet provided with your medication. For any questions or concerns about Trelegy Ellipta, consult your healthcare provider.



Reference: Trelegy Canada product monograph


Product Video: Canadian Trelegy